
UB189
TargetsB7H3 BsAb + Dual-payload
IndicationsSmall cell lung cancer
ClinicalEarly Phase
TherapeuticsOncology
ModalitiesADC
Exclusive Summary
- **Strategic Market Timing**: Targets the patent cliff window of the originator, offering partners a 'Day-1 Launch' opportunity to capture early generic market share.
- **Strong Clinical Demand**: Recognized as a first-line therapy in global guidelines for [Indication], addressing a massive patient population with rigid demand.
- **High Barrier & Differentiation**: Offers a distinct competitive edge with high technical or regulatory entry barriers, protecting partners from 'Red Ocean' price wars.
- **Cost Leadership**: Leverages an integrated supply chain (e.g., API + FDF) to provide superior cost-efficiency compared to Western competitors, maximizing partner margins.
- **Flexible Licensing Model**: Offers a ready-to-file Licensing-out package (including Dossier), significantly reducing R&D risks and time-to-market for partners.
Asset Materials

我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →